Abstract
Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Current Pharmaceutical Design
Title:An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies
Volume: 23 Issue: 4
Author(s): Weronika Wasinska-Borowiec, Kaveh Abri Aghdam, Jukka Matias Saari and Andrzej Grzybowski
Affiliation:
Keywords: Amiodarone, ethambutol, linezolid, methanol, phosphodiesterase 5 inhibitors, toxic optic neuropathy, tumor necrosis factor alpha inhibitors.
Abstract: Background: Toxic optic neuropathies (TONs) often present with a gradual and bilateral decrease in visual acuity, scotomas and optic disc pallor. Obtaining an accurate history is the critical first step in determining the etiology of TONs.
Methods: This updated review contains a thorough analysis of the current PubMed-indexed literature on the most common agents responsible for TONs, including methanol, ethambutol, amiodarone, linezolid, tumor necrosis factor alpha inhibitors and phosphodiesterase 5 inhibitors. Results: The reviewed articles are mainly case reports presenting new and controversial aspects of the above agents. New treatment strategies, such as erythropoietin for methanol optic neuropathy, are being proposed for TONs, a condition that was previously regarded as untreatable. Conclusion: TONs could cause significant disability due to visual impairment. In case of early diagnosis and drug withdrawal, most TONs are treatable. Patients need to be appropriately counseled, and prescribing physicians should be especially made aware of TON-inducing medications.Export Options
About this article
Cite this article as:
Wasinska-Borowiec Weronika, Aghdam Abri Kaveh, Saari Matias Jukka and Grzybowski Andrzej, An Updated Review on the Most Common Agents Causing Toxic Optic Neuropathies, Current Pharmaceutical Design 2017; 23 (4) . https://dx.doi.org/10.2174/1381612823666170124113826
DOI https://dx.doi.org/10.2174/1381612823666170124113826 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli
Current Neuropharmacology Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews Patent Selections
Recent Patents on DNA & Gene Sequences Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Antifungal Prophylaxis in the Neonatal Intensive Care Unit (NICU)
Current Pediatric Reviews Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation
Current Cardiology Reviews Current and Potential Use of Citrus Essential Oils
Current Organic Chemistry A Systems Biology Consideration of the Vasculopathy of Sickle Cell Anemia: The Need for Multi-Modality Chemo-Prophylaxis
Cardiovascular & Hematological Disorders-Drug Targets Potential of Flavonoids as Anti-inflammatory Agents: Modulation of Pro- Inflammatory Gene Expression and Signal Transduction Pathways
Current Drug Metabolism Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
Current Cardiology Reviews Multimodal Optical, X-Ray CT, and SPECT Imaging of a Mouse Model of Breast Cancer Lung Metastasis
Current Molecular Medicine L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Anti-Selectin Therapy for the Treatment of Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry